Dr. Bob Discordia leads CaaMTech’s pharmaceutical development team in advancing a portfolio of novel compounds from the company’s vast library into clinical trials. Bob comes to CaaMTech with an abundance of pharmaceutical and biotechnology industry experience stemming from a distinguished 26-year career with Bristol Myers Squibb. He started as a research chemist working on the development of the revolutionary anticancer drug Taxol® (paclitaxel) and went on to lead many key programs for the company. Later, he became an executive within Business Operations responsible for the external strategic partnerships for the Global Pharmaceutical Development and Manufacturing and Supply organizations. More recently, Bob was Chief Operating Officer and Head of CMC Development for Corbus Pharmaceuticals. Under his direction, Corbus expanded its capabilities in its run-up to the launch of its first pharmaceutical product. He subsequently founded Avanzarx Pharmaceuticals, a virtual biotech developing novel technology for the treatment of inflammatory and fibrotic diseases.